Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.
Sculpher
Mark
M
D000077556:Alitretinoin; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D000068818:Cetuximab; D003362:Cost-Benefit Analysis; D003659:Decision Making, Organizational; D003879:Dermatologic Agents / Q000191:economics / Q000627:therapeutic use; D004485:Eczema / Q000188:drug therapy / Q000191:economics; D019317:Evidence-Based Medicine; D035082:Federal Government; D006229:Hand Dermatoses / Q000188:drug therapy / Q000191:economics; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000191:economics; D006801:Humans; D038622:Internationality; D009313:National Health Programs; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy / Q000191:economics; D010380:Peer Review; D019057:Quality-Adjusted Life Years; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D014212:Tretinoin / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D000077556:Alitretinoin; D014212:Tretinoin; D000068818:Cetuximab
Pharmacoeconomics. 2010;28(2):143-52
20085390
Pharmacoeconomics. 2008;26(12):1037-43
19014204
Pharmacoeconomics. 2010;28(2):93-102
20085386
Pharmacoeconomics. 2010;28(2):153-62
20085391
Pharmacoeconomics. 2010;28(2):109-11
20085388
Pharmacoeconomics. 2010;28(2):105-7
20085387
Pharmacoeconomics. 2010;28(5):351-62
20131924
Health Policy. 2008 Sep;87(3):389-400
18387689
Pharmacoeconomics. 2010;28(2):163-70
20085392
Value Health. 2009 Mar-Apr;12(2):193-201
18700865
Pharmacoeconomics. 2010;28(2):113-42
20085389
Pharmacoeconomics. 2010;28(6):439-48
20465313